Einloggen
E-Mail
Passwort
Passwort anzeigen
Merken
Passwort vergessen?
Werden Sie kostenlos Mitglied
Registrieren
Registrieren
Mitglied werden
Kostenlos registrieren
Abonnent werden
Unser Angebot
Einstellungen
Einstellungen
Dynamische Kurse 
OFFON

BIOGEN INC.

(BIIB)
  Bericht
ÜbersichtKurseChartsNewsRatingsTermineUnternehmenFinanzenAnalystenschätzungenRevisionenDerivate 
ÜbersichtAlle NewsAnalystenempfehlungenAndere SprachenPressemitteilungenOffizielle PublikationenBranchen-NewsMarketScreener Analysen
Nachrichten in anderen Sprachen über BIOGEN INC.
16:41Ionis Pharma Shares Drop 12% After Tofersen Study Misses Primary Endpoint
16:38IONIS PHARMACEUTICALS : Partner Biogen Says Tofersen Study Failed to Meet Primary Goal; Sh..
14:50BIOGEN : résultats d'étude décevants dans la SLA
13:32BIOGEN : Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Exte..
10:12BIOGEN : Tofersen Misses Primary Endpoint But Still Shows Signs of Reduced Disease Progres..
17.10.BIOGEN : Announces Topline Results from the Tofersen Phase 3 Study and its Open-Label Exte..
17.10.BIOGEN : trial of ALS drug fails main goal, but company says data are encouraging
15.10.L'agenda della prossima settimana -2-
15.10.Analysis-Deals, data buzz could help biotech shares exit Wall St's 'no man's land'
15.10.Deals, data buzz could help biotech shares exit Wall St's 'no man's land'
14.10.BIOGEN : Topline Results from Tofersen Phase 3 Study and its Open Label Extension in SOD1-..
14.10.Biogen Inc. Announces Topline Results from Tofersen Phase 3 Study and Its Open Label Ex..
14.10.BIOGEN : New Data at ECTRIMS 2021 Highlight Biogen's Focus on Patient-Centered Outcomes an..
14.10.BIOGEN : New MS PATHS Data at ECTRIMS 2021 Confirm Biogen's Disease-Modifying Therapies Do..
13.10.BIOGEN : Preliminary Analysis Suggests Certain Multiple Sclerosis Therapies May Reduce COV..
13.10.BIOGEN : New Data at ECTRIMS 2021 Highlight Biogen's Focus on Patient-Centered Outcomes an..
13.10.Biogen Inc. Announces New Data from its Industry-Leading Portfolio of Multiple Sclerosi..
13.10.BIOGEN : New MS PATHS Data at ECTRIMS 2021 Confirm Biogen's Disease-Modifying Therapies Do..
13.10.BIOGEN : People Treated With MS Therapies Achieve Antibody Response to Covid-19 Vaccinatio..
06.10.BIOGEN : to Report Third Quarter 2021 Financial Results October 20, 2021
06.10.BÖRSE WALL STREET : Less tech, more energy
06.10.ANALYST RECOMMENDATIONS : American Airlines, Biogen, Morgan Stanley, Rolls-Royce, United S..
04.10.Sage Therapeutics and Biogen Announces Consistent Clinically Meaningful Data for Zurano..
29.09.IMPRESE : Europe's Best Workplaces 21, Italia conta 20 aziende premiate
28.09.BIOGEN : Partner Eisai Launches Rolling Submission of Biologics License Application With F..
28.09.BIOGEN : Eisai Initiates Rolling Submission To The U.S. FDA For Biologics License Applicat..
23.09.BIOGEN : Issues First Progress Report of its Signature Healthy Climate, Healthy Lives&trad..
22.09.VC DAILY : Indian Ed-Tech Startup Boosts U.S. Expansion With Summer Deals
21.09.BIOGEN : FDA Approves Samsung Bioepis and Biogen's BYOOVIZ (SB11), LUCENTIS Biosimilar (ra..
21.09.BIOGEN : 2021 Investor R&D Day
21.09.BIOGEN : R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potenti..
20.09.BIOGEN : MS Portfolio
20.09.BIOGEN : Gene Therapy
20.09.BIOGEN : Biomarkers
20.09.BIOGEN : Biotherapeutics and Medicinal Sciences at Biogen
20.09.BIOGEN : Human Genetics
20.09.BIOGEN : Movement Disorders at Biogen
20.09.BIOGEN : Digital Health
20.09.BIOGEN : Advancements in Research
20.09.BIOGEN : Alzheimer's Disease Research Portfolio
20.09.BIOGEN : CHMP Recommends VUMERITY (diroximel fumarate) for Approval in the European Union ..
20.09.BIOGEN : Samsung Bioepis' Byooviz Approved by FDA
20.09.BIOGEN : FDA Approves Samsung Bioepis and Biogen's BYOOVIZ™ (SB11), LUCENTIS® Biosim..
20.09.FDA Approves Samsung Bioepis and Biogen’s BYOOVIZ, LUCENTIS Biosimilar (ranibizumab-nun..
20.09.Biogen, Samsung Bioepis Get FDA OK for Lucentis Biosimilar
19.09.ALZHEIMER : un nouvel espoir, timide, pour traiter la maladie
19.09.Alzheimer, la démence la plus connue
18.09.Preview -- Barron's
17.09.BIOGEN : Vumerity Receives Marketing Recommendation From European Medicines Agency
17.09.CHMP Recommends VUMERITY® (diroximel fumarate) for Approval in the European Union as a ..
17.09.Biogen Inc. Receives Approval from European Medicines Agency for VUMERITY in the Europe..
17.09.MODERNA : U.S. FDA advisers may vote on COVID-19 boosters for older adults after rejecting..
17.09.Biogen Gets CHMP Backing for Vumerity in Multiple Sclerosis
16.09.BIOGEN : Plans to Initiate Phase 3b Study Evaluating Potential Benefit of a Higher Dose of..
16.09.BIOGEN : Study of Vixotrigine in Small Fiber Neuropathy Meets One Endpoint, Misses Another..
16.09.BIOGEN : Announces Positive Topline Results from Phase 2 CONVEY Study in Small Fiber Neuro..
16.09.Biobiogen Inc. Announces Positive Topline Results from Phase 2 Convey Study in Small Fi..
16.09.Biogen Drug Candidate for Small Fiber Neuropathy Meets Primary Endpoint for 200 Milligr..
15.09.BIOGEN : Announces Agenda for Virtual Investor Day R&D Day on September 21, 2021
15.09.Correction to Biogen Plans Phase 3b Trial Article
15.09.BIOGEN : to Conduct Phase 3b Study of Higher Dose of Nusinersen in Patients Previously Tre..
15.09.BIOGEN : Plans to Initiate Phase 3b Study Evaluating Potential Benefit of a Higher Dose of..
15.09.Biogen Inc Announces Plans to Initiate Global Phase 3B Clinical Study, ASCEND
15.09.Biogen Plans Phase 3b Trial of Spinal Muscular Atrophy Drug
10.09.S&P 500 Limps Into Close as Late Sell-Off Caps Worst Week Since February
10.09.VIDEO : This week's gainers and losers
10.09.PUMP / DUMP #28 : Les Tops & Flops de la semaine
10.09.Japan's Topix hits highest since 1990 on hopes of new govt, better earnings
10.09.Wall Street : s'essouffle au final, mais repli sans intensité
10.09.Japan shares rally on, Topix hits over 30-year high on earnings optimism
09.09.Wall Street : s'essouffle au final, mais repli sans intensité
09.09.US Stocks Retreat as Jobless Claims Drop More Than Expected
09.09.US Stocks End Lower After Larger-Than-Expected Decline in Jobless Claims
09.09.Wall Street finit en baisse, faute de quoi maintenir son élan
09.09.Equities Edge Higher Midday After Jobless Claims Drop More Than Expected
1  2  3  4  5  6  7  8  9  10Weiter